Literature DB >> 2478795

The positive inotropic effect of pimobendan involves stereospecific increases in the calcium sensitivity of cardiac myofilaments.

R J Solaro1, K Fujino, N Sperelakis.   

Abstract

We have studied the effect of pimobendan (UD-CG 115 BS) on the electrical, mechanical, and biochemical activity of intact and detergent-skinned preparations of cardiac muscle. Racemic pimobendan increased the contractile force of guinea pig papillary muscle preparations and this positive inotropic action was associated with potentiation of the Ca2+-dependent slow action potentials (APs). However, in the presence of 25 mM [K]0 and maximally activating concentrations of isoproterenol, isometric force was increased further by addition of 50 microM pimobendan with no effect on the slow action potential. Experiments with chemically skinned heart muscle fibers showed that pimobendan, in a dose-dependent manner, increased active tension developed at submaximally activating concentrations of Ca2+. The tension-cost (unit increase in ATPase rate/unit increase in force) was unchanged in the presence of pimobendan. Force-pCa and ATPase-pCa relations of skinned fiber preparations contracting isometrically were shifted to the left by 0.15-0.20 pCa units in the presence of 50 microM pimobendan. The mechanism for this effect was shown to be an increase in the Ca affinity of the regulatory binding sites of troponin C (TNC). These effects are due mainly to the l optical isomer of pimobendan. Addition of either the d or l isomer of pimobendan to preparations. maximally stimulated by 1 microM isoproterenol, did not affect the slow AP parameters, but did increase contractile force to 124% of control by the d isomer and to 184% of control by the l isomer. The Ca2+-sensitizing effect of l-pimobendan on skinned fiber preparations was substantially greater than that of the d isomer.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2478795

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  11 in total

1.  Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure.

Authors:  Miki Nonaka; Sachio Morimoto; Takashi Murayama; Nagomi Kurebayashi; Lei Li; Yuan-Yuan Wang; Masaki Arioka; Tatsuya Yoshihara; Fumi Takahashi-Yanaga; Toshiyuki Sasaguri
Journal:  Br J Pharmacol       Date:  2015-03-17       Impact factor: 8.739

2.  Comparison of the effects of levosimendan, pimobendan, and milrinone on canine left ventricular-arterial coupling and mechanical efficiency.

Authors:  P S Pagel; D A Hettrick; D C Warltier
Journal:  Basic Res Cardiol       Date:  1996 Jul-Aug       Impact factor: 17.165

3.  Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs.

Authors:  P S Pagel; D A Hettrick; D C Warltier
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

4.  Effect of pimobendan in patients with chronic heart failure.

Authors:  N Takeda; Y Hayashi; T Arino; A Takeda; K Noma
Journal:  Exp Clin Cardiol       Date:  2001

5.  Reversal of phosphate induced decreases in force by the benzimidazole pyridazinone, UD-CG 212 CL, in myofilaments from human ventricle.

Authors:  L D Fraker; J Van Eyk; R J Solaro
Journal:  Mol Cell Biochem       Date:  1997-11       Impact factor: 3.396

6.  A Potent Fluorescent Reversible-Covalent Inhibitor of Cardiac Muscle Contraction.

Authors:  Fangze Cai; Thomas Kampourakis; Brittney A Klein; Brian D Sykes
Journal:  ACS Med Chem Lett       Date:  2021-08-23       Impact factor: 4.632

7.  Use of pimobendan in feline congenital heart failure.

Authors:  Shannon Wainberg
Journal:  Can Vet J       Date:  2013-12       Impact factor: 1.008

Review 8.  Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.

Authors:  A Fitton; R N Brogden
Journal:  Drugs Aging       Date:  1994-05       Impact factor: 3.923

9.  Low concentrations of UD-CG 212 enhance myocyte contractility by an increase in calcium responsiveness in the presence of inorganic phosphate.

Authors:  J C van Meel; N Redemann; W Diederen; R M Haigh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-06       Impact factor: 3.000

10.  Defining the binding site of levosimendan and its analogues in a regulatory cardiac troponin C-troponin I complex.

Authors:  Ian M Robertson; Olga K Baryshnikova; Monica X Li; Brian D Sykes
Journal:  Biochemistry       Date:  2008-06-21       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.